NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study
4/8/2014 9:30:45 AM
BERLIN--(BUSINESS WIRE)--NOXXON Pharma announced that data from a Phase IIa pilot study in anemic cancer patients treated with lexaptepid pegol (NOX-H94) will be presented today at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA.
Lexaptepid pegol is a Spiegelmer® that binds and neutralizes hepcidin, a peptide hormone that negatively regulates serum iron levels. High hepcidin levels, commonly found in patients with cancer or in dialysis patients, lead to iron restriction, also known as functional iron deficiency: a condition in which iron is blocked inside its cellular stores and is thus unavailable for hemoglobin synthesis. This condition, over time, results in anemia of chronic disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by